{
    "clinical_study": {
        "@rank": "13397", 
        "arm_group": [
            {
                "arm_group_label": "Peginterferon alfa 2a", 
                "arm_group_type": "Active Comparator", 
                "description": "Peginterferon alfa 2a 180 mcg"
            }, 
            {
                "arm_group_label": "Peginterferon Lambda", 
                "arm_group_type": "Experimental", 
                "description": "Peginterferon Lambda 60,120,180 and 240 mcg"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open label, dose ranging, phase1a/1b clinical trial to study the safety,\n      Pharmacokinetics and Pharmacodynamics of Peglamda 60, 120, 180 and 240 mcg in healthy\n      volunteers and antiviral activity of once weekly Peglamda administration in combination with\n      daily Ribavirin in Hepatitis C naive patients up to 4 weeks period. The objective of the\n      study to establish safety, PK/PD data on healthy subjects and preliminary efficacy and\n      safety in Hepatitis C naive patients."
        }, 
        "brief_title": "The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Phase 1a: The subjects who are willing to participate in Phase 1a study must meet ALL of\n        the following inclusion criteria:\n\n          1. Volunteers (male and female) between the ages of 18-45\n\n          2. Women have a negative pregnancy test result at the time of study.\n\n          3. Clinical examination and result laboratory for 7 days before starting the trial must\n             be inside the normal range.\n\n          4. Currently not following any treatment regimen (except for using the oral\n             contraceptive).\n\n          5. Body mass index is between the range and / or not 25% difference compared to the\n             normal BMI (Appendix 6).\n\n          6. Be able to comply with protocol and exchange information effectively with the\n             researchers, agree on the written informed consent to participate in the clinical\n             trial\n\n        Phase 1b: Subjects willing to participate into the phase 1b study must meet ALL of the\n        following inclusion criteria:\n\n          1. Patients with chronic hepatitis C (male and female).\n\n          2. Ages between 18 - 65 years old.\n\n          3. Female patient (or female partners of the male patients) with negative pregnancy test\n             results and/or apply effective contraception if still having sex during the study and\n             for 6 months after using the last dose of Ribavirin.\n\n          4. No previous treatment with IFN or IFN treatment with rapid viral response or already\n             have completely viral response but leave the treatment early.\n\n          5. HCV-RNA levels in serum > 80 IU / mL.\n\n          6. The haematological and biochemical (except ALT / AST) parameters must be within\n             normal limits.\n\n          7. Body weight in the normal range of 25% difference compared to the normal BMI\n             (Appendix 6)\n\n          8. Be able to comply with protocol and exchange information effectively with the\n             researchers, agree on the written informed consent to participate in the clinical\n             trial\n\n        Exclusion Criteria:\n\n        Phase 1a: Subjects with at least 1 of the following exclusion criteria are considered\n        ineligible to participate in Phase 1a study:\n\n          1. With a history of drug abuse, alcohol or drug using within 1 year before taking part\n             in the clinical trial. AUDIT-C scale (WHO) will be used to assess the use of alcohol.\n             The score \u2265 4 in men or \u2265 3 in women are considered as alcoholics.\n\n          2. History of depression\n\n          3. History of chronic diseases related to the respiratory system, cardiovascular,\n             gastrointestinal, malignant disease affecting to the function of the organ systems.\n             Having any interferon or antiviral therapy within 4 months before the trial\n\n          4. Participate in any clinical trial within 3 months prior the testing\n\n          5. Use of any drug in the last period of relatively positive test which last\n             approximately 6 times the half-life of the drug.\n\n          6. Blood donor with more than 400 mL of blood within 3 months prior the testing\n\n          7. Influenza infection or cold symptoms within 2 weeks before the trial\n\n          8. Having positive tests of HBV, HCV or HIV\n\n          9. Breastfeeding women\n\n        Phase 1b: Subjects with at least 1 of the following exclusion criteria are considered\n        ineligible to participate in Phase 1b study:\n\n          1. Co-infection with hepatitis B and/or HIV.\n\n          2. Hepatic Impairment\n\n          3. Cirrhosis\n\n          4. Positive tests with antibody of Peginterferon lambda 1 and Peginterferon alpha 2a.\n\n          5. History of chronic diseases related to the respiratory system, cardiovascular,\n             gastrointestinal, malignant disease affecting to the function of the organ systems.\n\n          6. A history of immune disorders (eg, inflammatory bowel disease, hemorrhagic\n             thrombocythemia, lupus erythematosus, autoimmune hemolytic anemia, autoimmune\n             disease, scleroderma, severe psoriasis, arthritis rheumatoid ...)\n\n          7. A history of severe mental illness, especially depression, especially the serious\n             neurological condition determined as depression or serious psychological disorders,\n             suicidal intention, or being hospitalized for mental illness, or having 1 phase of\n             impaired function due to neuropathy.\n\n          8. A history of severe epilepsy or using antiepileptic drugs.\n\n          9. A history of using anti-cancer agents (including radiation therapy) or immunotherapy\n             (including systematic corticosteroids) within 6 months before using the first testing\n             dose or the patient may be in need of this treatment during the trial\n\n         10. History of organ transplants with the presence of the graft function.\n\n         11. Evidence of alcohol or drugs abuse within 1 year before the trial. AUDIT scale - C\n             will be used to assess the use of alcohol. The score \u2265 4 in men or \u2265 3 in women are\n             considered as alcoholics\n\n         12. History or evidence of severe disease or any other condition based on the\n             investigator assessment that the subject may not be suitable for this study.\n\n         13. Breastfeeding women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063607", 
            "org_study_id": "NNG01"
        }, 
        "intervention": {
            "arm_group_label": [
                "Peginterferon alfa 2a", 
                "Peginterferon Lambda"
            ], 
            "intervention_name": "Peginterferon lambda", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2a"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Hepatitis C naive", 
        "lastchanged_date": "February 13, 2014", 
        "location": {
            "contact": {
                "last_name": "Dr.Chinh Trong Nguyen, PhD"
            }, 
            "contact_backup": {
                "last_name": "Dr.Quang Ngoc Nguyen, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Hanoi", 
                    "country": "Vietnam", 
                    "zip": "10000"
                }, 
                "name": "The Military 108 Hospital"
            }, 
            "investigator": {
                "last_name": "Dr.Chinh Trong Nguyen, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Vietnam"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients", 
        "overall_contact": {
            "email": "hongnga@nanogenpharma.com", 
            "last_name": "Dr.Nga Hong Le, Msc", 
            "phone": "+84-979776110"
        }, 
        "overall_contact_backup": {
            "email": "kiranbabu@nanogenpharma.com", 
            "last_name": "Mr.Kiran babu K, M.Pharm", 
            "phone": "+84-938916645"
        }, 
        "overall_official": {
            "affiliation": "The Military 108 Hospital", 
            "last_name": "Dr.Chinh Trong Nguyen, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Vietnam: Drug Administration of Vietnam"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Concentration-Time Curve (AUC 0-336)", 
                "safety_issue": "Yes", 
                "time_frame": "0, 6, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 336 hours"
            }, 
            {
                "measure": "Percentage of Patients achieving Rapid Virological Response (RVR)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063607"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of subjects with incidence of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "15 days"
        }, 
        "source": "Nanogen Pharmaceutical Biotechnology Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nanogen Pharmaceutical Biotechnology Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}